Bipolar Disorder – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Bipolar disorder (BPD) is a chronic illness characterized by recurrent episodes of aberrant mood; patients may exhibit manic, depressive, or mixed symptoms between periods of stable mood. Treatment for BPD is highly individualized owing to variations in patients’ symptom profiles and drug responses. Antiepileptic drugs such as the staple BPD treatment lamotrigine, atypical antipsychotics such as quetiapine and aripiprazole, antidepressants such as sertraline, and other agents may be prescribed alone or as combination therapy to address the condition. The BPD market is highly genericized and price-conscious, posing a challenge for newer branded agents entering the market. Our Treatment Algorithms Claims Data Analysis provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for BPD.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed BPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed BPD patients?
- How have Latuda, Vraylar, and Caplyta been integrated into the treatment algorithm, and what is their source of business?
- What percentage of BPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of BPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: AbbVie, Alkermes, Intra-Cellular Therapies, Sumitomo Pharma / Sunovion
Key drugs: Vraylar, Caplyta, Lybalvi, Latuda, lithium, lamotrigine, sertraline, quetiapine, aripiprazole, benzodiazepines
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Matthew D. Litke, M.S., :ead Healthcare Research & Data Analyst, CNS and Ophthalmology. Mr. Litke supports Clarivate’s Treatment Algorithms Claims Data Analysis report series, in addition to authoring syndicated content in the CNS and ophthalmology therapy areas. He holds a B.S. in biochemistry and molecular biology from Penn State University and an M.S. in psychology from Villanova University.